Welcome New Members!

Posted by ISPE Boston
On December 5, 2018

We would like to introduce the Members who joined ISPE in November 2018, welcome them to the Chapter and encourage them (and all of our members) to take advantage of the many professional development, networking and information resources available through ISPE. Fellow ISPE members are a terrific resource for help with everyday professional challenges. And […]

New Triple-Drug Therapy from Vertex Shows Promise

Posted by ISPE Boston
On November 30, 2018

Vertex Pharmaceuticals has announced that treatment with the triple combination of the next-generation corrector VX-659, tezacaftor and ivacaftor resulted in statistically significant improvements in lung function in two Phase 3 studies in people with cystic fibrosis (CF). Vertex also today announced that enrollment is complete for the two Phase 3 studies of the triple combination […]

Designing, Building & Operating Manufacturing Facilities for Novel Therapeutics

Posted by ISPE Boston
On November 29, 2018

Design of manufacturing facilities for the production of novel therapeutics requires careful planning and consideration of a myriad of factors, such as throughput, biosafety level, product segregation and contamination control, regulatory environment, time to market, and tech transfer challenges. It is a complex mix of elements and requires a project team that can move quickly […]

Study Describes Causes of Gender Gap in MA Life Sciences Sector, Recommends Solutions

Posted by ISPE Boston
On November 26, 2018

“Opening the Path to a Diverse Future” contains the results of an exhaustive study examining the causes leading to the lack of gender diversity within the Massachusetts life sciences sector. The study was undertaken by the Massachusetts Biotechnology Council (MassBio) and executive recruiting company Liftstream. The resulting report, the most extensive of its kind, explores […]

Fall Social Highlights Friendship and “Life Sciences Cares”

Posted by ISPE Boston
On November 15, 2018

The Annual Fall Social was full of energy with hugs, handshakes and the clinking of glasses as attendees convened on Thursday, October 25 at Meadhall in Cambridge. Over 100 attendees joined together to celebrate Autumn Harvest & ISPE Community (this year’s Fall Social theme) and enjoy connecting with friends and colleagues both old and new. […]

Tango Therapeutics and Gilead Sciences to Collaborate on Immuno-Oncology

Posted by ISPE Boston
On November 12, 2018

Cambridge-based Tango Therapeutics, a company focused on the discovery and development of novel cancer therapies, has announced a global strategic collaboration with Gilead Sciences to discover, develop and commercialize a pipeline of innovative targeted immuno-oncology treatments for patients with cancer. Under the multi-year collaboration, Tango will perform target discovery and validation and Gilead will have […]

Chapter Member Anniversaries: October 2018

Posted by ISPE Boston
On November 8, 2018

Please congratulate the following members celebrating milestone anniversaries in October 2018. Their dedication to ISPE, the Boston Area Chapter and the industry is applauded! Over Twenty Years Dr. Michael T. Ku, PharmD, MBA, Pfizer Inc John S. Magyar, Parsons Infrastructure & Technology Ric Feldt, Jeff Smith & Associates Stephen R. Higham, PE, Sanofi Peter […]

Welcome New Members!

Posted by ISPE Boston
On November 8, 2018

We would like to introduce the Members who joined ISPE in October 2018, welcome them to the Chapter and encourage them (and all of our members) to take advantage of the many professional development, networking and information resources available through ISPE. Fellow ISPE members are a terrific resource for help with everyday professional challenges. And […]

GO Therapeutics Inks Deal with Roche

Posted by ISPE Boston
On November 1, 2018

Cambridge-based GO Therapeutics, a company applying new advances in glycoproteomics to develop antibody-based cancer therapeutics, announced in early October that it has entered into a license agreement with Roche. The agreement grants Roche a worldwide, exclusive license for antibodies generated to address a novel cancer-specific target. Under the terms of the agreement, Roche will pay […]

Paratek Wins FDA Approval of “Modernized” Tetracycline

Posted by ISPE Boston
On November 1, 2018

Boston-based Paratek Pharmaceuticals has announced that the FDA has approved Nuzyra (omadacycline) for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute skin and skin structure infections (ABSSSI). Nuzyra, a modernized tetracycline, is a once-daily IV and oral antibiotic that exhibits activity across a spectrum of bacteria, including Gram-positive, Gram-negative, atypicals, and drug […]

Page 77 of 90«‹75 767778 79 ›»